Polyclonal Anti-FGFR3

Price

200.00 USD

Size

100ug/vial

Reactivities

Hum, Rat

Format

Each vial contains 5mg BSA, 0.9mg NaCl, 0.2mg Na2HPO4, 0.05mg Thimerosal, 0.05mg NaN3.

References

1. Almeida, M. R., Campos-Xavier, A. B., Medeira, A., Cordeiro, I., Sousa, A. B., Lima, M., Soares, G., Rocha, M., Saraiva, J., Ramos, L., Sousa, S., Marcelino, J. P., Correia, A., Santos, H. G. Clinical and molecular diagnosis of the skeletal dysplasias associated with mutations in the gene encoding fibroblast growth factor receptor 3 (FGFR3) in Portugal. Clin. Genet. 75: 150-156, 2009.\n2. Barroso, E., Perez-Carrizosa, V., Garcia-Recuero, I., Glucksman, M. J., Wilkie, A. O., Garcia-Minaur, S., Heath, K. E. Mild isolated craniosynostosis due to a novel FGFR3 mutation, p.Ala334Thr. Am. J. Med. Genet. 155A: 3050-3053, 2011. \n

Storage Temp

At -20 degree C for one year. After reconstitution, at 4 degree C for one month. It can also be aliquotted and stored frozen at -20 degree C for a longer time.Avoid repeated freezing and thawing.

Scientific Background

Fibroblast growth factor receptor 3, also known as CD333, is a protein that in humans is encoded by the FGFR3 gene. This gene encodes a member of the fibroblast growth factor receptor (FGFR) family, with its amino acid sequence being highly conserved between members and among divergent species. The FGFR3 gene is mapped to the HD region on chromosome 4p16.3. The extracellular portion of the protein interacts with fibroblast growth factors, setting in motion a cascade of downstream signals, ultimately influencing mitogenesis and differentiation. This particular family member binds acidic and basic fibroblast growth hormone and plays a role in bone development and maintenance. Mutations in this gene lead to craniosynostosis and multiple types of skeletal dysplasia.